Cancer Diagnostics

The cancer diagnostic test that Sierra Sciences has is the same proprietary high throughput robotic screening assay, called the High Throughput hTERT Expression Detection Assay, that Sierra Sciences already routinely uses to screen cells treated with pharmaceuticals and nutraceuticals to see if the pharmaceuticals or nutraceuticals induce the expression of telomerase.

85% of all cancers express telomerase as a result of mutations and/or chromosome rearrangements to the chromosomes of the cancer cells. These mutations and chromosomal rearrangements are usually caused by the pre-existing cancer cells’ short telomeres. Since the only other cells in the human body that express telomerase are the very rare primordial germ cells, any other cells in the body that are found to produce telomerase are most likely cancer cells.

This assay is >95% reliable in identifying a biopsy specimen submitted for testing as cancerous and ~85% reliable in identifying a biopsy specimen submitted for testing as not cancerous. No other diagnostic that exists today to detect early-stage cancers is as reliable as this.

The Cancer Diagnostics Market size valued at over USD 104.8 billion in 2019 and is expected to grow at 8.5% CAGR between 2020 and 2026. See: https://www.gminsights.com/industry-analysis/cancer-diagnostics-market?gclid=CjwKCAiAp4KCBhB6EiwAxRxbpDjKtHZcSfVW3tKkViZtvenlgLTbwHKPJ5jM_x78dsg3fsiB3DIxQxoCu4wQAvD_BwE. As just stated above, Sierra Sciences diagnostic will be far more accurate than any other cancer diagnostic, so Sierra Sciences diagnostic should capture a significant portion of the market.

No research required. It is ready to go. Will just require training.